



MATERIOVIGILANCE PROGRAMME OF INDIA:

A STRATEGY FOR MEDICAL DEVICE SAFETY ASSURANCE

¹Neeta Singh, ²Sagarika Majhi, ³Rohit Kumar

¹ Student of Master of Pharmaceutical Science

² Assistant Professor, ITS College of Pharmacy, Ghaziabad

³ Rohit Kumar, Associate Professor, Mission College Pharmacy, Varanasi

¹ Pharmacology

¹ Student of M. Pharma, Ghaziabad, India

Abstract:

This article manages the utilization, job, and exchange parts of medical devices regularly utilized in emergency clinics. Medical devices are the instrument hardware programming framework material or distinctive article that is utilized for indicative and remedial capacities for treatment the of sicknesses in human. Medical device assume a partner vital part in pharmacologic activity especially in treating technique there are a unit sizable number of devices are blessing especially in the pharmacologic field in the clinic, i.e., clinical area. Post marketing surveillance of medical device has been started in numerous nations; however, it is as yet not as evolved and strong as that of medications. Materiovigilance is the organized arrangement of recognizable proof, assortment, detailing, and examination of any untoward events related to the utilization of medical device and assurance of patient's wellbeing by forestalling its repeats. Materiovigilance is the examination and follow-up of occurrences that may result from the utilization of the medical device. It empowers to recognize the unfavourable occasions related to the utilization of Medical device. Service of Health and Family Welfare, Govt. of India endorsed and initiated Materiovigilance Program of India (MvPI) in the country to screen the wellbeing of Medical Devices Associated Adverse Events (MDAEs) in the Indian Population. The MvPI was dispatched on 06th July 2015 at the Indian Pharmacopeia Commission (IPC), Ghaziabad by the Drugs Controller General India (DCG(I)). All medical services experts, patients/buyers can report MDAEs to Sree Chitra Tirunal Institute of clinical Sciences and innovation (SCTIMST), Thiruvananthapuram, or National Coordination Centre (NCC) - IPC. The gathered and produced wellbeing information will assist with offering suggestions to the Central Drugs Standard Control Organization (CDSCO) for taking administrative choices on safe utilization of clinical gadgets in the Indian Population.

KEYWORDS: Materiovigilance programme of India (MvPI), Adverse Drug Reaction (ADR), WHO-Uppsala monitoring Centre (WHO-UMC), Medical device adverse events (MDAEs), Materiovigilance Regulation, Clinical case studies, Cataract surgery.

INTRODUCTION: The expression "vigilance" signifies close checking of the conceivable adverse event [1-4]. Materiovigilance is the investigation of unfavourable occasions related to the utilization of clinical gadgets. It manages the nearby observing of a medical device after the post-showcasing stage [1, 5] The expression "medical device" has been characterized by the World Health Organization (WHO) as an instrument, device, reagent for in vitro use, embed, gadget for tissue cutting or wound covering, exceptionally modern modernized clinical hardware, programming or other related or comparable materials which are proposed to be utilized for analysis, anticipation, checking, treatment of illness [1, 4-7]. A Medical device is characterized as any instrument, hardware, material or other article utilized all alone or mutually, including programming needed for it to work effectively, which is proposed by the maker to be utilized on people for the accompanying purposes:

- For symptomatic, avoidance, control, treating, or decreasing a sickness.
- For demonstrative, control, treating, for diminishing or remunerating a physical issue or impairment.
- For contemplating, supplanting, or changing a piece of the life structures of a physiological interaction.
- For dominating conception

To screen the wellbeing of the utilization of medical devices in the country, the Ministry of Health and Family Welfare, Govt. of India maintained and started the Materiovigilance Program of India (MvPI) in the country. The MvPI was dispatched on 06th July 2015 at the Indian Pharmacopeia Commission, Ghaziabad by the Drugs Controller General India (DCG(I)). I Indian Pharmacopeia Commission (IPC) is a free association under the Ministry of Health and Family government help and functions as National Coordination Centre for the Materiovigilance Program of India. Sree Chitra Tirunal Institute of clinical Sciences and development (SCTIMST), Thiruvananthapuram will fill in as a National Collaborating Centre for MvPI. Particular assistance for the program is to be given by the Division of Healthcare Technology, a proposed WHO cooperating with the local area for need clinical contraptions and prosperity development technique in the National Health Systems Resources Centre.[2] The diagrammatic portrayal of the accomplices of the Materiovigilance Program of India is referenced in figure 1.




Figure 1: Diagrammatic representation of the partners of the Materiovigilance programme of India.[2]

The MvPI aims to gather the security information in an efficient way with the goal that the suggestions and administrative choices on safe utilization of medical devices can be taken dependent on the information produced in the Indian Population. The program is intended to screen medical device-related unfriendly occasions (MDAEs) and make mindfulness among medical services experts about the significance of MDAEs detailing in India and checking the advantage hazard profile of the medical device. It is additionally intended to create autonomously, proof put together proposals concerning the security of the medical device and further to impart the discoveries to every one of the critical stakeholders in the country and the stakeholders of the Pharmacovigilance Program of India (PvPI).

Scope and objective of Materiovigilance:

The chief reason for Materiovigilance is

1. To improve the insurance of wellbeing security of the patients, clients, and others by diminishing the recurrence of an occurrence [2, 3].
2. To investigate the proposed construction, and its idea, for the Indian Medical device carefulness structure to overall harmonization, i.e., Global Harmonization Task Force (GHTF) [6]
3. To bring answers for the progression of the utilization and efficiency of the gear [8]
4. To make a cross-country framework for patient wellbeing checking.
5. To examine the danger advantage proportion of medical devices utilized. To create proof put together information concerning the security of medical devices.

6. To help Central Drugs Standard Control Organization (CDSCO) in the unique collaboration on the use of the clinical devices. To convey wellbeing data on the utilization of medical devices to different partners to limit the danger.
7. To arise as a public focus of greatness for Materiovigilance exercises. To team up with other medical care associations and global organizations for the National Coordination Centre trade of data and information the board [4, 7].
8. manufacturer, importer, distributor of medical device, including all medical care partners for better comprehension of medical device norms for the advancement of patient wellbeing and fortifying of Materiovigilance framework.
9. To mindful partners about the need and meaning of medical device adverse event (MDAE) reporting.

Materiovigilance program of India (MvPI):

In India, clinical gadgets are named drugs and are directed by medications and corrective demonstration and rule 1945 [6, 7]. The MvPI is needed to control the quality, adequacy, security, and accessibility of medical devices. The medical device rules, 2017 was brought to control the creation, import, bargains, appointment of clinical devices and came into power from 1 January 2018 [9]. The Central Licensing Approving Authority in October 2005, reported 10 devices to be considered as medication. A Medical device which is named drugs incorporates heart stents, drugs eluting stents, preventative inserts, catheters, bone concrete, i.e., cannula, intraocular focal points, and so on [6, 10]. The MvPI targets checking adverse events related to the clinical gadgets (clinical gadget-related unfriendly occasions). In this program, the IPC capacities as a public organizing focus and CDSCO as a controller (fig. 1). The MvPI incorporates all private and general medical care conveyance frameworks just as the e-announcing framework. The MvPI was embraced by the Ministry of Health and Family Welfare on 10/2/15 and it was dispatched on 06/7/15 by DCGI at IPC, Ghaziabad, India [1, 5]

Arrangement of Medical gadgets:

Medical gadgets are described by each regulatory master in their specific way. By and large, the reason for medical devices is delegated based on the danger related to the medical devices, producers' planned reason for the device, and the device's signs for use [6, 11].

Characterization of medical devices by the United States Food and Drug Administration (USFDA):

USFDA has ordered medical devices into three classes based on the degree of control important to guarantee the security and viability of the device and based on data about advertising prerequisites and has assembled them into 16 clinical claims to fame (table 1) [6].

Table 1: Characterization of medical devices on the basis of USFDA

CLASS	NAME OF CLASS	EXAMPLES
CLASS I	General controls	Elastic Bandages and appraisal gloves
CLASS II	General controls and special controls	Implantation siphons, and ultrasound, Imaging frameworks.
CLASS III	General controls and premarket approval	Heat valves, and silicone gel-filled bosom embeds.

Notwithstanding various things, the class to which your gadget is apportioned chooses the kind of premarketing convenience required for USFDA slack to grandstand. On the off chance that the device is named Class I or II and not absolved, a 510k will be needed for showcasing. All gadgets named excluded face the limits on exclusions A Premarket Approval Application (PMA) will be required for class III gadgets with the exception of if the gadget is a pre-correction gadget (accessible before the medical device changes in 1976, or practically identical to such a gadget) and PMA's have not been called for. In such a condition, a 510k will be the course to advertise [6, 12].

Characterization of clinical gadget by the Therapeutic Good Administration (TGA):

The TGA has described clinical devices into five classes dependent on a lot of four gathering rules: invasive, non-invasive, active, and special kinds of gadgets, which are discussed in table 2 [6,]

Table 2: Characterization of medical devices on the basis of TGA

CLASS	RISK	EXAMPLES
CLASS I assessment lights	Low risk	Surgical magnifying lens and
CLASS IIa warming covers	Low to medium risk	Electrical needle treatment and
CLASS IIb defibrillators	Medium to high-risk	Infant hatcheries and outer
CLASS III natural heart valves	High risk	Heparin-covered catheters and
CLASS IV	Active implantable medical device (AIMD)	Prophylactic intrauterine contraptions

Grouping of a medical device by the Medicines and Healthcare items Regulatory Agency (MHRA)

In like manner, the MHRA has arranged medical device into various gatherings as [21]:

- General clinical gadgets

- AIMDs

- In vitro analytic medical device

As indicated by MHRA the overall clinical gadgets were then additionally arranged into four classes as depicted in given table 3 [13].

Table 3: MHRA characterization of general clinical gadgets

CLASS	RISK LEVEL	REQUIREMENTS
CLASS I	Low risk	Premarket warning
CLASS IIa	Low- medium risk	Certification by informed body
CLASS II b	Medium- high risk	Certification by informed body
CLASS III	High risk	Certification by advised body

In India, medical device is not portrayed dependent on the risk conversely with the coordinated country. Maybe, the 10-devices class of clinical gadgets has been told to be controlled as medications [6].

Table 4: Risk request as demonstrated by the New Zealand rules

AIMD	RISK	Implantable pacemaker
CLASS III	High	Drug eluting cardiovascular stents
CLASS IIb	Medium to high	Ventilators, muscular inserts
CLASS IIa	Medium to low	Hypodermic needles, pull hardware
CLASS I sterile	Low	Sterile dressings, non-cured
CLASS I measuring	Low	Volumetric urine pack
CLASS I basic	Low	Reusable careful instruments

Hazard grouping as indicated by the New Zealand guidelines

The New Zealand Regulations have five danger classes and two sub-classes by following the standards of the GHTF. In light of the premise of the potential danger presented by the medical device when utilized as planned by the producer, these are characterized into various classes as demonstrated in table 4 [14].

Adverse event reporting:

The adverse event reporting framework has been considered as an instrument to improve and secure the wellbeing and wellbeing of patients and clients, in this manner decreasing the probability of an adverse event, to forestall reiteration of antagonistic occasions, or to ease results of such redundancy. Despite the means taken by the GHTF to accomplish consistency among unfriendly occasion announcing frameworks, the framework varies in establishing part nations. The GHTF [15] gave the direction on obligatory detailing of unfriendly occasions for device makers and intentional announcing for clients. Additionally, the maker should choose the reportability of unfavourable occasions based on data access. The FDA's medical device reporting (MDR) regulations [16-19] require makers and merchants to report genuine wounds, passing's, and glitches, and client offices to report genuine wounds and passing's. The guidelines don't need an unfamiliar maker to meet FDA guidelines, however, whenever utilized, the

specialist could advance reports and will be seen as a representative of an unfamiliar firm. The TGA [20,21] has energized the detailing of antagonistic occasions by the producers and patrons as well as my clients. The EEC mandates incorporate necessities not just for makers or approved agents of the medical device to report specific types of occurrences to an equipped authority like the MHRA, yet in addition for the MHRA to spread the data to other capable specialists and the EEC. Additionally, in India, CDSCO looks at that as an unfavourable occasion that ought to be accounted for by the production.

Kinds of reports

The reports being submitted are resolved on the grounds of specified reporting periods. In this way, GHTF [22] has not suggested any report types for makers. The kind of report to be submitted contrasts among the managed nations, as the revealing time varies. The FDA [23] has decided the producer is needed to submit five MDR reports, i.e.,

1. 30-day report: should contain data on event of death, genuine injury, glitch, and announcing of occasions utilizing objection data.
2. 5-day report: is for the most part submitted for serious, surprising, or unforeseen occasions and those occasions that require quick healing activity or for which FDA has made a composed solicitation
3. Baseline report: should go with the relating structure 3500A when an occasion including the gadget model or gadget family is accounted for interestingly, giving essential gadget ID data. The report can be put together by model kind (one benchmark report for each model) or by gadget family (one standard report for all models in that family).
4. Supplemental report: should be submitted utilizing structure 3500A inside a multi-month (30 schedule days) after receipt of the extra data. The number of subsequent meet-ups would rely upon the nature and seriousness of the occasion revealed.
5. Annual certificate: the producer should assign more than one confirming authority, every one of whom should sign a certificate explanation for their distinguished authoritative segment or site. The confirmation is needed to limit the unexpected revealing blunders that have been submitted during the year time frame. The yearly confirmation must be submitted during the association's yearly enlistment date.

Notwithstanding, in the United Kingdom, [24,25] the producer or approved agent can report episodes by accommodation of following reports:

1. Initial Reporting of unfavourable occasion to MHRA for record and assessment
2. Periodic summary Reporting: these reports are submitted in an agreed form and recurrence for the device and incident between the maker and MHRA after accommodation of at least one starting report.
3. Trend reports: these reports should be submitted when there is a significant increase in the rate of effectively reportable occasions, episodes that are normally excluded from revealing, and occasions that are typically not reportable.
4. Final reports All device protests, potential use mistake occasions, and abnormal use occasions should be accounted for and researched by the maker. The producer should play out the examination after the underlying report in an interview with the client while illuminating the MHRA regarding the advancement through intermittent reports or pattern reports as fitting. If underlying appraisal includes a change of the gadget that may influence ensuing examination, the MHRA should be educated before continuing with adjustment. The TGA/, additionally has not decided the unmistakable report types for announcing unfavourable occasions by the producer, though CDSCO in India has decided notice reports as starting, last, or potentially pattern reports. The decision of report type relies upon the accessibility of material information inside the fitting report time.

Reporting of Medical Device related Adverse Events (MDAEs)

What to Report?

A wide range of suspected Medical Device related Adverse Events (MDAEs) can be accounted for whether they are serious or non-serious, known and unknown, frequent or rare paying little heed to a set up causal relationship. Any Adverse occasions related to the utilization of medical devices can be accounted for. Occurrence portrayal, Details of unfavourable occasion including the depiction of the device (inadequacy or malfunction), explanation of dangers related with the device and the related danger of patient, client or individual, any conceivable danger to patient-related with past use can be given in the MDAEs announcing structure. [26]

Where to Report MDAEs?

The Healthcare experts (clinicians, dental specialists, drug specialists, attendants) and patients/customers can report MDAEs to SCTIMST or NCCS suitably filled Medical Device Adverse Event Reporting Form

can be shipped off Sree Chitra Tirunal Institute of Medical Science and Technology (SCTIMST), National Collaboration Centre Materiovigilance Program of India, Biomedical Technology Wing, Pooja Pura, Thrivananthapuram 695012, Kerala, India Or Can clearly email the appropriately filled design to mvpi@sctimst.ac.in

Whom to Report MDAEs?

After filling the MDAEs announcing structure it very well may be straightforwardly submitted to NCC or SCTIMST. if the report is submitted straightforwardly to SCTIMST, these reports are affirmed and approved by medical services experts, following the passage of the case report into Vigiflow and shipped off NCC for additional appraisal. In the wake of getting the case report at NCC, All the cases, at last, were investigated and surveyed at NCC and focused on WHO-Uppsala Monitoring Center (WHO-UMC). The accommodation of the MDAEs report doesn't have any legitimate ramifications on the correspondents. The classification of the patients is rigorously kept up and secured to the furthest reaches. The accommodation of a report doesn't comprise a confirmation that the clinical workforce or the maker of the item caused or added to the occasion or response. In this way, medical services suppliers are urged to report MDAEs for better comprehension of the danger related to the utilization of medical devices and to shield the wellbeing of the Indian populace.

Post advertising stage

All the unfavourable occasions are observed by the producer during the utilization of their device and fundamental move is made which is otherwise called FSCA for the decrease in the danger of death or genuine fall in the condition of well-being related to the utilization of a clinical gadget that is set on the lookout.

The adverse incident report identified with the device is checked by the equipped experts in each state (EU part) in their own country, alongside the producer's examination and reactions. Materiovigilance is intended to create data for recognizable proof of the issues identified with the utilization of medical devices for the help of the advancement of wellbeing gadgets [2, 4, 27].

Medical device Tracking:

Medical gadget following has been consolidated by the FDA as one of the post-publicizing activities to follow the gadget from the hour of it gathering up to the end customer [6]. Medical device following aides in finding the device if there should be an occurrence of any imperfection or issues with the device [28]. As per the FDA Act, there is a sure device which requires following like implantable device, life-maintaining or life-supporting gadgets, the disappointment of such device will bring about genuine results. The rules did for the accompanying medical device got incredible on 29 august 1993 and can be found in 21 CFR segment 8216 [29].

The maker is expected to introduce the information concerning the medical device whether the devices has not or has been scattered to a patient inside a period of 3-10 d [30]. The maker needs to build up a composed standard working system for following the medical device which incorporates techniques and other data in regards to the following of the medical device. The following is by and large performed for a class II and class III device. TGA has developed an Implantable Medical Device Tracking Subcommittee (IMDTS) for the accompanying patients with implantable clinical devices. Regardless, in Europe, the Adverse Incident Tracking System (AITS) should be followed. The unfriendly occasions can be ordered into one of the accompanying investigational classifications as indicated by the updated MHRA orders [30]:

1. The producer is expected to introduce the information with respect to the clinical Devices whether the devices have not or has been scattered to a patient inside a period of 3-10 d [6]. The maker needs to build up a composed standard working system for following the medical device which incorporates techniques and other data in regards to the following of the medical device. The following is by and large performed for a class II and class III device.

2. TGA has developed an Implantable Medical Device Tracking Subcommittee (IMDTS) for the accompanying patients with implantable medical devices. Regardless, in Europe, the Adverse Incident Tracking System (AITS) should be followed. The unfriendly occasions can be ordered into one of the accompanying investigational classifications as indicated by the updated MHRA orders [6]:

Although as of now more than 90% of cataract medical procedures include implantation of Intra Ocular Lens (IOLs), the antagonistic occasions related to IOLs are for the most part announced from the west. [31,32,33] However, unfavourable occasions of IOLs are less or not revealed in the Indian populace as security concerns, conceivably as the partners probably won't know about the detailing framework and its importance. A portion of the main points of interest identified with IOLs are poor visual results because

of coronas, glare, starbursts, crack of the focal point haptic saw previously or during addition, the disappointment of the focal point to open, injector disappointment or breaks or breaks in the focal point. Also, around one in each 2500 day by day dispensable contact focal point clients and one in each 500 expanded wear delicate focal point clients foster assumed microbial Keratitis consistently [6] however such data is inaccessible from India. Glaucoma seepage devices are progressively discovering acknowledgment among glaucoma experts as an option to trabeculectomy in specific conditions. It was because of documentation of unfriendly occasions that a few gadgets have been adjusted or even removed. As the antagonistic occasion reports identified with a device collect with time, fundamental examinations about the item can be started, which may bring about changes to the item or its withdrawal from the market. This won't just assistance in added wellbeing for the patients yet in addition help in the turn of events and examination of ophthalmic devices. Sadly, because of the absence of revealing device-related entanglements, there is an inability to distinguish possible issues and consequently open patients to pointless dangers.

CONCLUSION: Materiovigilance program of India plans to gather, assess, and break down information identified with the wellbeing of the device in an orderly way. In any case, for its prosperity, every one of the partners related with the assembling, showcasing, and utilization of medical devices should be made mindful of the significance of producing wellbeing information, archiving unfriendly occasions, and answering to the MvPI. Materiovigilance program is a decent drive by the various nations to guarantee the wellbeing of medical devices among device users worldwide. This is essential that vehement execution of this program will repayment the wellbeing of gadget clients or patients. This program will be likewise fundamentally lessening the danger identified with the utilization of medical devices by forestalling the reduplication of aversive impacts. The medical device is of different assortments, some space utilized for recognition and few are symptomatic capacities. These medical devices got to use by good mentors and taught people to have the protected and viable use of those medical devices. Data device and characterization are fundamental because the medical device includes three significant groupings inside which Category III, which is the closest class, would compel authority leeway before they are promoted. This is appropriate to a device that is considered to life-supporting or life maintaining or are set up to the body Class II devices ought to conform to guidelines to be exposed either by groups are from outside the Government or by the Government. Classification I are oppressed into "general control" which infers it is this is regularly appreciating the "general perceived as protected." Therefore, depending on the opportunity clinical consideration should be taken all through the work of the medical device. Besides, conjointly all through the procurement of medical device should ensure the agency endorsement with regards to its group for the protected and viable remedial reason.

REFERENCE:

1. Rani S, Singh K. Materiovigilance: an emerging discipline. *Int J Sci Res* 2018; 7:15-6.
2. Materiovigilance in EU. Lambda therapeutic research ltd; 2019. <https://www.lambda-cro.com/materiovigilance-in-eu/> [Last accessed on 26 Oct 2018]
3. Madhusudan SK, Shashikala GH. Evaluation of knowledge, awareness, and practice of pharmacovigilance among practicing doctors. *Asian J Pharm Clin Res* 2016;9 Supple 3:283-6.
4. Sivadasan S, Sellappan M. A study on the awareness and attitude towards pharmacovigilance and adverse drug reaction reporting among nursing students in a private university, Malaysia. *Int J Curr Pharm Res* 2015; 7:84-9.
5. Kumar P, Kalaiselvan V, Kaur I, Thota P, Singh GN. Materiovigilance programme of India (MVPI): A step towards patient safety for medical devices. *Eur J Biomed Pharm Sci* 2016; 12:497-501.
6. Gupta P, Janodia MD, Jagadish PC, Udupa N. Medical device vigilance systems: India, US, UK, and Australia. *Med Devices (Auckl)* 2010; 3:67.
7. Meher BR. Materiovigilance: an Indian perspective. *Perspect Clin Res* 2018; 9:175-8.
8. Dieffaga T, Sango M, Maiga S. P360: Materiovigilance and improvement of the maintenance of the biomedical equipment by the implementation of strategies for the use of equipment: case study of the hospital Gabriel Touré of Mali. *Antimicrob Resist Infect Control* 2013;2 Suppl 1: P360.
9. Classification of medical devices and in vitro diagnostic medical devices under the provisions of the medical devices rules. Drugs Controller General, India; 2017. Available from: <http://www.cdsc.nic.in/writereaddata/Classification%20wise%20list%20of%20MD%20and%20IVDs17.pdf> [Last accessed on 01 Nov 2018].

10. Wathoni N, Alfauziah TQ, Rantika N. Evolution of contraceptive implants: a review. *Int J Appl Pharm* 2018; 10:16-22.
11. Principles of medical devices classification. The global harmonization task force; 2006. Available from: <http://www.imdrf.org/docs/ghrf/final/sg1/technical-docs/ghrf-sg1-n15-2006-guidance-classification-060627.pdf> [Last accessed on 01 Nov 2018].
12. Classify Your Medical Device. USFDA; 2018. Available from: <https://www.fda.gov/medicaldevices/deviceregulationandguidance/overview/classifyyourdevice/ucm2005371.htm> [Last accessed on 22 Jan 2019]
13. Medicines and Healthcare products regulatory agency. Available from: <https://www.gov.uk/topic/medicines-medical-devices-blood/medical-devices-regulation-safety> [Last accessed on 13 Feb 2019].
14. Risk classification of medical devices. New Zealand Medicines and Medical Devices Safety Authority; 2011. Available from: <https://medsafe.govt.nz/regulatory/devicesnew/3-7RiskClassification.asp> [Last accessed on 01 Nov 2018]
15. Medical devices post market surveillance: global guidance for adverse event reporting for medical devices. 2006 Nov. <http://www.ghrf.org/GHrf/SG2/N54R8:2006>. Accessed 2009 Oct 25.
16. Medical device reporting for manufacturers. 1997 Mar. <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094529.htm>. Accessed 2009 Aug 10.
17. Medical device reporting: manufacturer reporting requirements. 2008 Apr. <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance>. Accessed 2009 Aug 10
18. Reporting adverse events (medical devices). 2009 Aug. <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/ReportingAdverseEvents/default.htm>. Accessed 2009 Aug 10.
19. Medical device reporting: user facility reporting requirements. 2008 Apr. <http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM095266.pdf>. Accessed 2009 Aug 11.
20. Australian medical device guidelines: postmarket activities. 2003. <http://www.tga.gov.au/pdf/devguid11.pdf>. Accessed 2009 Aug 14
21. Australian medical device guidelines: obligations and responsibilities of medical device manufacturers and sponsors. 2003. <http://www.tga.gov.au/docs/html/devguid20.htm>. Accessed 2009 Aug 14
22. Medical devices post market surveillance: global guidance for adverse event reporting for medical devices. 2006 Nov. <http://www.ghrf.org/GHrf/SG2/N54R8:2006>. Accessed 2009 Oct 25.
23. Medical device reporting for manufacturers. 1997 Mar. <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094529.htm>. Accessed 2009 Aug 10
24. Making medical device vigilance more effective. 2007 Nov. <http://www.mhra.gov.uk/NewsCentre/CON2033159>. Accessed 2009 Aug 11.
25. New medical devices vigilance guidance system MEDDEV version 5. <http://www.mhra.gov.uk/Publications/Regulatoryguidance/Devices/DirectivesBulletins/CON2033888>. Accessed 2009 Aug 15
26. Kalaiselvan V, Kumar P, Mishra P, Singh GN. System of adverse drug reactions reporting: What, where, how and whom to report? *Indian J Crit Care Med.*, 2015; 19: 564-6. 6. Kalaiselvan V, Mishra P, Parvizi N, Woods K. Regulation of medicines and medical devices: contrasts and similarities. *Clin Med (Lond)* 2014; 14:6-12.
28. MDR Adverse Event Codes. USFDA; 2018. Available from: <https://www.fda.gov/medicaldevices/deviceregulationandguidance/postmarketrequirements/reportingadverseevents/mdradverseeventcodes/default.htm> [Last accessed on 19 Dec 2018].
29. Golder S, Wright K, Rodgers M. Failure or success of search strategies to identify adverse effects of medical devices: a feasibility study using a systematic review. *Syst Rev* 2014;3:1-6.
30. Stapleton F, Keay L, Jalbert I, Cole N. The epidemiology of contact lens related infiltrates. *Optom Vis Sci.* 2007; 84:257-72. [PubMed] [Google Scholar]
31. Plager DA, Lynn MJ, Buckley EG, Wilson ME, Lambert SR. Complications in the first 5 years following cataract surgery in infants with and without intraocular lens implantation in the Infant Aphakia Treatment Study. *Am J Ophthalmol.* 2014; 158:892-8. [PMC free article] [PubMed] [Google Scholar]
32. *VISION2020 | THE RIGHT TO SIGHT INDIA* [Google Scholar]

33. Stein JD. Serious adverse events after cataract surgery. *Curr Opin Ophthalmol.* 2012; 23:219–25. [PMC free article] [PubMed] [Google Scholar]

